Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
Shares of Perspective Therapeutics (CATX) are down $1.52, or 34%, to $2.97 after the radiopharmaceutical company announced that updated interim ...
Discover ATAI’s pipeline, including promising BPL-003 for TRD, upcoming Phase 3 trials, and a merger with Beckley Psytech.
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine ...
TipRanks on MSN
Genmab announces new data from Phase 1/2 RAINFOL-01 trial
Genmab (GMAB) announced updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan, an investigational folate ...
Genmab A/S(Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S ® ), an investigational folate receptor alpha ...
LONDON, GREATER LONDON, UNITED KINGDOM, October 14, 2025 /EINPresswire.com/ -- How Big Is The Targeted Alpha-Therapy Market In 2025? The market for targeted alpha-therapy has seen a significant surge ...
FDA grants orphan drug designation to cintredekin besudotox, offering new hope for glioblastoma treatment with targeted delivery methods. The FDA has granted orphan drug designation to cintredekin ...
Sanofi reports that its AlphaMedix phase 2 trial showed strong efficacy and survival benefits in gastroenteropancreatic ...
AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback